Evidence map›Paper›PMID 41474640›Full record

ArticleJournal of veterinary pharmacology and therapeutics2026

Functional Characterization of the Cat and Dog Wild-Type and Mutant MDR1 Carrier Proteins and Frequency of the MDR1 Gene Mutation in 800 Cats From Germany.

Lisa Siegl, Mies Bethäuser, Daniela Nürnberger, Stefan Oswald, Andreas Moritz, Melanie Hamann, Joachim Geyer

Abstract read
In one paragraph

Article in Journal of veterinary pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lisa SieglInstitute of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Biomedical Research Center Seltersberg (BFS), Justus Liebig University of Giessen, Giessen, Germany.
Mies BethäuserInstitute of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Biomedical Research Center Seltersberg (BFS), Justus Liebig University of Giessen, Giessen, Germany.
Daniela NürnbergerInstitute of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Biomedical Research Center Seltersberg (BFS), Justus Liebig University of Giessen, Giessen, Germany.
Stefan OswaldInstitute of Pharmacology and Toxicology, Rostock University Medical Center, University of Rostock, Rostock, Germany.ORCID https://orcid.org/0000-0001-6269-4368
Andreas MoritzClinic of Small Animals-Internal Medicine, Faculty of Veterinary Medicine, Justus Liebig University Giessen, Giessen, Germany.
Melanie HamannInstitute of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Biomedical Research Center Seltersberg (BFS), Justus Liebig University of Giessen, Giessen, Germany.
Joachim GeyerInstitute of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Biomedical Research Center Seltersberg (BFS), Justus Liebig University of Giessen, Giessen, Germany.ORCID https://orcid.org/0000-0003-2663-1858

Funding

Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL, Braunschweig/Berlin, Germany) via the pharmacovigilance programDeutsche Forschungsgemeinschaft 505943254
6 · The paper itself

Abstract

The ATP-binding cassette transporter MDR1 P-glycoprotein (syn. ABCB1) is an efflux carrier at the cell membrane that regulates drug absorption, distribution, and elimination. At the blood-brain barrier, MDR1 restricts brain entry of potentially neurotoxic drugs, such as ivermectin. In dogs and cats, MDR1 (syn. ABCB1) gene deletion mutations exist that have been associated with increased neurological toxicity after ivermectin treatment. The present study found an allelic frequency of 0.625% for the MDR1 mutation in 800 cats from Germany. In addition, the canine and feline mutant and wild-type MDR1 proteins were expressed in HEK293 and MDCKII cells, and transport experiments were performed with the fluorescent MDR1 probe substrate rhodamine 123. In both cell lines, significant MDR1-mediated rhodamine 123 efflux was identified for the wild-type MDR1 proteins, but not for the mutant MDR1 proteins, confirming a complete loss-of-function phenotype due to MDR1 gene mutation. Competitive in vitro studies showed inhibition of both wild-type MDR1 carriers with the reference MDR1 inhibitors verapamil (IC

Indexed as

ATP Binding Cassette Transporter, Subfamily B, Member 1AnimalsATP Binding Cassette Transporter, Subfamily BCatsDogsGene FrequencyGermanyHEK293 CellsHumansIvermectinMadin Darby Canine Kidney CellsMutationRhodamine 123ATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1IvermectinRhodamine 123digoxindrug sensitivityHEK293ivermectinMDCKMDR1 (ABCB1)mutationP‐glycoproteintransporttranswell

Identifiers

PMID41474640
PMCPMC13159774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.